JaDeVin

Anthera Pharmaceutical ... -80%

NASDAQ:ANTH   ANTHERA PHARMACEUTICALS INC
This is biotech "at its best".
An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions.
And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ...

Luckily, I closed one trade with a win for this stock.

Conclusion: Stay away from small biotech firms!
MS Bahasa Melayu
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
HE עברית
Laman Utama Penyaring Saham Penyaring Forex Penyaring Kripto Kalendar Ekonomi Bagaimana ia berfungsi Ciri-ciri Carta Peraturan Dalaman Moderator Laman web dan Penyelesaian Broker Widget Perpustakaan Carta Stok Permintaan Ciri Blog & Berita Soalan Lazim Bantuan & Wiki Twitter
Profil Tetapan Profil Akaun dan Pengebilan Tiket Sokongan Saya Hubungi Sokongan Idea-idea yang diterbitkan Pengikut Mengikuti Mesej Peribadi Perbualan Daftar Keluar